Voyager Therapeutics, Inc. Share Price
NASDAQ: VYGR | Micro CapVoyager Therapeutics, Inc. Stock Performance
Open $3.12 | Prev. Close $3.10 | Circuit Range N/A |
Day Range $3.10 - $3.17 | Year Range $2.94 - $5.54 | Volume 5,646 |
Average Traded $3.14 |
Voyager Therapeutics, Inc. Share Price Today
As of 9 August 2026, Voyager Therapeutics, Inc.'s share price is $3.13. The stock opened at $3.12, compared to its previous close of $3.10. During today's trading session, Voyager Therapeutics, Inc.'s share price traded between $3.10 and $3.17, with an average price of $3.14. Over the past 52 weeks, the stock has recorded a high of $5.54 and a low of $2.94. In terms of performance, Voyager Therapeutics, Inc.'s share price has declined by 23.84% over the last six months and is down 7.12% on a year-on-year basis.
Voyager Therapeutics, Inc. Share Price Chart
Voyager Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $183.70M | PE Ratio (TTM) -1.53 | Dividend Yield N/A |
EPS (TTM) $-2.04 | Revenue (TTM) $40.37M | Return On Equity (TTM) -61.06% |
Profit Margin -296.53% | Debt to Equity 0.14 | Quarterly Earnings Growth YoY -208.40% |
Voyager Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Voyager Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Voyager Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $3.08 | $3.13 | +3.30% |
Jul 2026 | $3.55 | $3.03 | -13.18% |
Jun 2026 | $3.85 | $3.49 | -9.82% |
May 2026 | $3.71 | $3.87 | +3.75% |
Apr 2026 | $3.91 | $3.73 | -3.49% |
Mar 2026 | $4.05 | $3.87 | -5.96% |
Feb 2026 | $3.91 | $4.11 | +5.12% |
Jan 2026 | $3.87 | $3.91 | -0.51% |
Dec 2025 | $3.95 | $3.93 | -3.79% |
Nov 2025 | $4.63 | $4.08 | -12.43% |
Oct 2025 | $4.57 | $4.67 | -0.32% |
Sep 2025 | $3.35 | $4.68 | +38.87% |
VYGR Share Price FAQs
What is Voyager Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Voyager Therapeutics, Inc. stock?
What is VYGR's market capitalisation today?
What is VYGR's net income for the last quarter?
What is the 5 year returns of VYGR?
What is the high & low stock price of VYGR today?
Can I buy VYGR shares in India?